Loading organizations...
Loading organizations...
Intersect ENT is a technology company.
Intersect ENT develops and commercializes localized drug delivery devices for patients with ear, nose, and throat conditions. Their primary innovations include bioabsorbable, drug-eluting sinus implants such as PROPEL and SINUVA, designed to maintain sinus patency and deliver anti-inflammatory medication directly to the sinus mucosa following surgery. These products offer a targeted approach to managing inflammation and improving patient outcomes in the ENT space.
The company was founded in 2003 by Don Eaton, who sought to address unmet needs in rhinology through novel medical device technology. Eaton established the company in Menlo Park, California, driven by the insight that localized, sustained drug delivery within the sinuses could significantly enhance post-operative care and reduce recurrence of inflammation, moving beyond traditional systemic treatments.
Intersect ENT’s products are utilized by ear, nose, and throat specialists to improve the quality of life for patients recovering from sinus procedures. The company’s vision centers on transforming patient care by pioneering innovative, evidence-based solutions that offer superior outcomes and reduce the need for more invasive interventions in the treatment of chronic rhinosinusitis.
Intersect ENT has raised $114.0M across 5 funding rounds.
Intersect ENT has raised $114.0M in total across 5 funding rounds.
Intersect ENT has raised $114.0M in total across 5 funding rounds.
Intersect ENT's investors include Casper de Clercq, Norwest Venture Partners, Kleiner Perkins, Medtronic, PTV Sciences, U.S. Venture Partners, Mark Fletcher.
Intersect ENT was a medical technology company specializing in innovative treatments for ear, nose, and throat (ENT) conditions, particularly chronic rhinosinusitis (CRS). It developed PROPEL™ and SINUVA™ sinus implants, bioabsorbable devices that mechanically prop open sinus passageways post-surgery while locally delivering mometasone furoate, an anti-inflammatory steroid, to reduce inflammation and aid healing.[1][3][5] These products served ENT surgeons and patients suffering from CRS, a costly condition affecting millions, by addressing recurrent sinus obstruction and nasal polyps through less invasive, targeted therapy in hospitals, ambulatory centers, and office settings.[1][3][4][5] The company also offered tools like the VenSure™ balloon sinus dilation system and Cube™ navigation system before divesting them.[1][2] Intersect ENT was acquired by Medtronic in May 2022, integrating its core implants into Medtronic's broader ENT portfolio for enhanced global reach.[1][3]
Founded in 2003 and headquartered in Menlo Park, California, Intersect ENT emerged from a focus on localized drug delivery for ENT diseases, building on steroid-releasing implant technology to improve outcomes for CRS patients.[3][7] Led by CEO Thomas West, the company gained traction with PROPEL, FDA-approved for post-sinus surgery use, and SINUVA for office-based treatment of nasal polyps in patients with prior ethmoid surgery.[3][5][6] Key milestones included clinical validation showing reduced need for post-operative interventions and expansion into balloon dilation tools like VenSure and Cube systems.[2] The pivotal moment came in August 2021 when Medtronic announced its $1.1 billion acquisition, closing in May 2022, after which Intersect's employees and IP joined Medtronic, while Fiagon-brand navigation products were divested.[1][3]
Intersect ENT rode the wave of advancing minimally invasive ENT interventions, capitalizing on CRS as one of the top 10 costliest U.S. health conditions, driven by rising chronic disease prevalence and demand for outpatient procedures.[1][4] Timing aligned with post-2010 balloon sinuplasty adoption and steroid implant approvals, enabling faster patient recovery and reduced healthcare costs.[2][3] Market forces like aging populations, pollution-related sinus issues, and Medtronic's global infrastructure amplified its reach, influencing the ecosystem by setting standards for localized therapy that integrated with navigation and powered tools.[1][3] Post-acquisition, its tech bolsters Medtronic's Neuroscience portfolio, accelerating innovation in a $10B+ ENT market.[1][4]
Intersect ENT's legacy endures within Medtronic, where PROPEL and SINUVA continue evolving to treat more CRS patients globally, potentially expanding indications like nasal polyps via ongoing trials.[5][6] Trends in personalized medtech, AI-guided navigation, and biologics for inflammation will shape its trajectory, enhancing combo therapies for complex ENT cases. As Medtronic leverages its scale, Intersect's implants could redefine CRS care, solidifying its role from standalone innovator to cornerstone of comprehensive sinus solutions—proving targeted tech transforms patient access in a high-burden field.[1][3]
Intersect ENT has raised $114.0M across 5 funding rounds. Most recently, it raised $30.0M Series D in February 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2013 | $30.0M Series D | Casper de Clercq | Norwest Venture Partners, Kleiner Perkins, Medtronic, PTV Sciences, U.S. Venture Partners |
| Nov 1, 2010 | $30.0M Other Equity | Kleiner Perkins, Mark Fletcher, PTV Sciences, U.S. Venture Partners | |
| Oct 1, 2010 | $31.0M Series C | Norwest Venture Partners | |
| Jun 1, 2008 | $20.0M Series B | Norwest Venture Partners | |
| Sep 1, 2007 | $3.0M Series A | Norwest Venture Partners |